Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On February7, 2018, Axovant Sciences Ltd. (the “Registrant”) issued a press release announcing its financial results for the three and nine months ended December31, 2018. A copy of this press release is furnished herewith as Exhibit99.1 to this Current Report and is incorporated herein by reference.
In accordance with General Instruction B.2. ofForm8-K,the information in this Item 2.02, and Exhibit99.1 hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.
Item 2.02 Financial Statements and Exhibits.
Axovant Sciences Ltd. Exhibit
EX-99.1 2 a123118ex991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates–Expanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis,…
To view the full exhibit click
About Axovant Sciences Ltd. (NYSE:AXON)
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.